Bruce A. Cree

Neurology

1651 4th St Ste 252
San Francisco, CA 94158

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 232 publications

Diurnal step count patterns in progressive multiple sclerosis.

Diurnal step count patterns in progressive multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 18, 2026

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Journal: JAMA neurology

Published: August 17, 2026

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 21, 2026

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Journal: Annals of neurology

Published: March 17, 2026

Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.

Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: March 13, 2026

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Journal: JAMA neurology

Published: February 16, 2026

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Journal: medRxiv : the preprint server for health sciences

Published: February 06, 2026

Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.

Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.

Journal: Annals of clinical and translational neurology

Published: December 26, 2025

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Journal: Frontiers in immunology

Published: December 19, 2025

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Journal: Neurology and therapy

Published: December 16, 2025

Closing the referral gap: The role of a quality improvement initiative to enhance pelvic health physical therapy referrals for persons with multiple sclerosis-related bladder symptoms.

Closing the referral gap: The role of a quality improvement initiative to enhance pelvic health physical therapy referrals for persons with multiple sclerosis-related bladder symptoms.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: December 11, 2025

Showing 1-12 of 232

Last Updated: 09/26/2026